Phaseline

Companies › Neurodawn Pharmaceutical

Neurodawn Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Y-4
combination of pregabalin (GABA analog) and riluzole (glutamate release inhibitor)
GABRA1, SLCX1Phase 2Postherpetic NeuralgiaNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07275762Y-4Phase 2Postherpetic NeuralgiaOtherNov 2026

Targets

GABRA1 (1) SLCX1 (1)

Companies with the same targets

Ono Pharmaceutical Seaport Therapeutics Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Sedana Medical Acacia Pharma Umecrine Cognition

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.